Novartis said that Zortress (everolimus) has been cleared by the US Food and Drug Administration to help adult patients with kidney transplants keep the transplanted organ. The drug is already approved as an immunosuppressant and a cancer drug.
Novartis said that Zortress (everolimus) has been cleared by the US Food and Drug Administration to help adult patients with kidney transplants keep the transplanted organ. The drug is already approved as an immunosuppressant and a cancer drug.